These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 23931438)
1. Clinical pharmacology of novel anti-Alzheimer disease modifying medications. Caraci F; Bosco P; Leggio GM; Malaguarnera M; Drago F; Bucolo C; Salomone S Curr Top Med Chem; 2013; 13(15):1853-63. PubMed ID: 23931438 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463 [TBL] [Abstract][Full Text] [Related]
3. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Blennow K; Zetterberg H; Rinne JO; Salloway S; Wei J; Black R; Grundman M; Liu E; Arch Neurol; 2012 Aug; 69(8):1002-10. PubMed ID: 22473769 [TBL] [Abstract][Full Text] [Related]
4. The past, present, and future of disease-modifying therapies for Alzheimer's disease. Suzuki K; Iwata A; Iwatsubo T Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305 [TBL] [Abstract][Full Text] [Related]
5. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease. Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018 [TBL] [Abstract][Full Text] [Related]
7. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS; Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461 [TBL] [Abstract][Full Text] [Related]
8. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development. Ising C; Stanley M; Holtzman DM Clin Pharmacol Ther; 2015 Nov; 98(5):469-71. PubMed ID: 26250900 [TBL] [Abstract][Full Text] [Related]
9. Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates. Viayna E; Sabate R; Muñoz-Torrero D Curr Top Med Chem; 2013; 13(15):1820-42. PubMed ID: 23931440 [TBL] [Abstract][Full Text] [Related]
10. [Alzheimer's disease: New therapeutic strategies]. Villegas S Med Clin (Barc); 2015 Jul; 145(2):76-83. PubMed ID: 25245784 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic strategies for Alzheimer's disease in clinical trials. Godyń J; Jończyk J; Panek D; Malawska B Pharmacol Rep; 2016 Feb; 68(1):127-38. PubMed ID: 26721364 [TBL] [Abstract][Full Text] [Related]
12. Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. Montoliu-Gaya L; Villegas S Expert Rev Mol Med; 2016 Jun; 18():e13. PubMed ID: 27357999 [TBL] [Abstract][Full Text] [Related]
13. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P; Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Alzheimer's disease. Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646 [TBL] [Abstract][Full Text] [Related]
15. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies. Rygiel K Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098 [TBL] [Abstract][Full Text] [Related]